Clinical Trial: Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209631) titled 'Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients' on Sept. 29.

Brief Summary: This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.

Study Start Date: Oct. 01, 2024

Study Type: OBSERVATIONAL

Condition: Serum Lipoprotein(A) Severity Coronary Artery Disease Aortic Valve Sclerosis

Intervention: OTHER: Serum Lipoprotein-a level

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10...